RxDoctor Payments Data

Bradley Crombie, MD

Internal Medicine · Tallmadge, OHNPI 1134118540

Payments from drug & device makers

$3,927in general payments, 2019–2025

Across 280 payments — averaging $14.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$785
  • Novo Nordisk$453
  • Amgen$259
  • Bayer$216
  • Amarin Pharma, Inc.$207
  • Pfizer$199
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$3,85298%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,927 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$73,920
Medicare patients
224
Services billed
1,695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban140$154,976
OzempicSemaglutide97$119,154
JardianceEmpagliflozin62$80,724
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$57,208
TrulicityDulaglutide29$56,492
KerendiaFinerenone31$45,764
ProliaDenosumab18$31,000
FarxigaDapagliflozin Propanediol28$29,292
GlyxambiEmpagliflozin/Linagliptin15$24,032
JanumetSitagliptin Phos/Metformin Hcl20$19,925
XareltoRivaroxaban18$18,193
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$16,593
VascepaIcosapent Ethyl12$12,040
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$9,290
DuleraMometasone/Formoterol14$7,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$199$154,976140 claims
Novo NordiskOzempic$453$119,15497 claims
Boehringer IngelheimJardiance, Glyxambi, Synjardy$162$108,61190 claims
GSKTrelegy Ellipta, Anoro Ellipta$149$64,06867 claims
Lilly USA, LLCTrulicity$189$56,49229 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$138$49,59054 claims
BayerKerendia$216$45,76431 claims
AmgenProlia$259$31,00018 claims
MerckJanumet, Dulera$64$27,31134 claims
Johnson & JohnsonXarelto$81$18,19318 claims
AbbVieSynthroid$785$1,82768 claims
Sanofi-aventis U.S. LLCLantus$26$1,68416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Tallmadge

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →